title: Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis.
abstract: Pulmonary mucormycosis (PM) is a life-threatening opportunistic mycosis with a variable clinical evolution and few prognostic markers for outcome assessment. Several clinical risk factors for poor outcome present at the diagnosis of PM were analyzed in 75 consecutive hematology patients from 2000-2012. Significant variables (P < 0.1) were entered into a multivariate Cox-proportional hazard regression model adjusting for baseline APACHE II to identify independent risk factors for mortality within 28 days. Twenty-eight of 75 patients died within 4-week follow up. A lymphocyte count < 100/mm³ at the time of diagnosis (adjusted hazard ratio 4.0, 1.7-9.4, P = 0.01) and high level of lactate dehydrogenase (AHR 3.7, 1.3-10.2, P = 0.015) were independent predictors along with APACHE II score for 28-day mortality. A weighted risk score based on these 3 baseline variables accurately identified non-surviving patients at 28 days (area under the receiver-operator curve of 0.87, 0.77-0.93, P < 0.001). A risk score > 22 was associated with 8-fold high rates of mortality (P < 0.0001) within 28 days of diagnosis and median survival of 7 days versus ≥28 days in patients with risk scores ≤22. We found that APACHE II score, severe lymphocytopenia and high LDH levels at the time of PM diagnosis were independent markers for rapid disease progression and death.
authors.affiliation: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Russell E
authors.initials: RE
authors.lastname: Lewis
authors.forename: Sarah P
authors.initials: SP
authors.lastname: Georgiadou
authors.forename: Fotis
authors.initials: F
authors.lastname: Sampsonas
authors.forename: George
authors.initials: G
authors.lastname: Chamilos
authors.forename: Dimitrios P
authors.initials: DP
authors.lastname: Kontoyiannis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000150:complications / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000150:complications / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000150:complications / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality*; D011379:Prognosis; D012307:Risk Factors; D055815:Young Adult
keywords: Mucormycosis; lymphocytopenia; risk index score
references.citation: Haematologica. 2004 Feb;89(2):207-14
references.pmid: 15003897
references.citation: Clin Infect Dis. 2003 Jan 1;36(1):46-52
references.pmid: 12491201
references.citation: Haematologica. 2013 Apr;98(4):492-504
references.pmid: 22983580
references.citation: Clin Infect Dis. 2008 Aug 15;47(4):503-9
references.pmid: 18611163
references.citation: Infect Dis Clin North Am. 2006 Sep;20(3):581-607, vi
references.pmid: 16984870
references.citation: Clin Infect Dis. 2012 Feb;54 Suppl 1:S73-8
references.pmid: 22247449
references.citation: J Infect Dis. 2012 Jul 1;206(1):135-9
references.pmid: 22529315
references.citation: Antimicrob Agents Chemother. 2011 Nov;55(11):5018-21
references.pmid: 21876046
references.citation: Clin Infect Dis. 2005 Sep 1;41(5):634-53
references.pmid: 16080086
references.citation: Blood. 2003 Aug 1;102(3):827-33
references.pmid: 12689933
references.citation: Clin Microbiol Rev. 2005 Jul;18(3):556-69
references.pmid: 16020690
references.citation: Clin Infect Dis. 2000 Jun;30(6):851-6
references.pmid: 10852735
references.citation: Clin Microbiol Infect. 2011 Dec;17(12):1859-67
references.pmid: 21199154
references.citation: Blood. 2011 Aug 4;118(5):1216-24
references.pmid: 21622653
references.citation: Clin Infect Dis. 1999 Feb;28(2):322-30
references.pmid: 10064251
references.citation: Blood. 2011 Nov 17;118(20):5416-9
references.pmid: 21931119
references.citation: Br J Haematol. 1997 Nov;99(2):331-6
references.pmid: 9375750
references.citation: Clin Infect Dis. 2010 Jun 15;50(12):1559-67
references.pmid: 20450350
references.citation: Clin Infect Dis. 2012 Feb;54 Suppl 1:S35-43
references.pmid: 22247443
references.citation: Am J Med. 2012 Jan;125(1 Suppl):S25-38
references.pmid: 22196206
references.citation: Med Mycol. 2012 Aug;50(6):611-8
references.pmid: 22435877
references.citation: J Chemother. 2009 Jun;21(3):322-9
references.pmid: 19567354
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):e61-5
references.pmid: 16511748
references.citation: Clin Infect Dis. 2007 Feb 15;44(4):531-40
references.pmid: 17243056
references.citation: Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34
references.pmid: 22247442
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):955-63
references.pmid: 16511759
references.citation: Clin Infect Dis. 2008 Jun 15;46(12):1813-21
references.pmid: 18462102
references.citation: Clin Infect Dis. 2009 Jun 15;48(12):1743-51
references.pmid: 19435437